EcoDrugPlus

Eph Receptor A3

Ensembl ID : ENSMAUG00000011923
Gene Symbol: EPHA3
4 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSMAUG00000001045
Gene Symbol: EPHB4
3 Cross references
166 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSMAUG00000009598
Gene Symbol: EPHA2
1 Cross references
124 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMAUG00000015009
Gene Symbol: F2RL3
4 Cross references
197 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSMAUG00000014406
Gene Symbol: FAU
4 Cross references
251 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSMAUG00000010062
Gene Symbol: FKBP1A
2 Cross references
229 Possible Orthologues:

Fms-Like Tyrosine Kinase 3

Ensembl ID : ENSMAUG00000011952
Gene Symbol: FLT3
1 Cross references
133 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSMAUG00000018126
Gene Symbol: FXYD2
4 Cross references
74 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMAUG00000008178
Gene Symbol: FYN
4 Cross references
261 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSMAUG00000017036
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSMAUG00000010848
Gene Symbol: GPR84
3 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMAUG00000011232
Gene Symbol: HCK
3 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).